LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

SCHLIEREN, Switzerland & ROCKVILLE, Md.--(BUSINESS WIRE)--LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus). LimmaTech also receives an exclusive option, executable post Phase 1...

read more

InSphero Logo InSphero Strengthens its Executive Team by Appointing Paul Clémençon, MBA as Chief Business Officer

Zürich, Switzerland, December 14, 2023 InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team. Since joining the company in 2022 as the Head of Business Development, Paul has...

read more

Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement

Saint-Prex and Schlieren, Switzerland– 11 December, 2023 – Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to develop, manufacture and commercialize next generation microbiome-based therapeutics within...

read more